Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial

Background Artemisinin combination therapies (ACTs) are currently the preferred option for treating uncomplicated malaria. Dihydroartemisinin-piperaquine (DHA-PQP) is a promising fixed-dose ACT with limited information on its safety and efficacy in African children. Methodology/Principal Findings The non-inferiority of DHA-PQP versus artemether-lumefantrine (AL) in children 6–59 months old with uncomplicated P. falciparum malaria was tested in five African countries (Burkina Faso, Kenya, Mozambique, Uganda and Zambia). Patients were randomised (2∶1) to receive either DHA-PQP or AL. Non-inferiority was assessed using a margin of −5% for the lower limit of the one-sided 97.5% confidence interval on the treatment difference (DHA-PQP vs. AL) of the day 28 polymerase chain reaction (PCR) corrected cure rate. Efficacy analysis was performed in several populations, and two of them are presented here: intention-to-treat (ITT) and enlarged per-protocol (ePP). 1553 children were randomised, 1039 receiving DHA-PQP and 514 AL. The PCR-corrected day 28 cure rate was 90.4% (ITT) and 94.7% (ePP) in the DHA-PQP group, and 90.0% (ITT) and 95.3% (ePP) in the AL group. The lower limits of the one-sided 97.5% CI of the difference between the two treatments were −2.80% and −2.96%, in the ITT and ePP populations, respectively. In the ITT population, the Kaplan-Meier estimate of the proportion of new infections up to Day 42 was 13.55% (95% CI: 11.35%–15.76%) for DHA-PQP vs 24.00% (95% CI: 20.11%–27.88%) for AL (p<0.0001). Conclusions/Significance DHA-PQP is as efficacious as AL in treating uncomplicated malaria in African children from different endemicity settings, and shows a comparable safety profile. The occurrence of new infections within the 42-day follow up was significantly lower in the DHA-PQP group, indicating a longer post-treatment prophylactic effect. Trial Registration Controlled-trials.com ISRCTN16263443

[1]  Organización Mundial de la Salud.  Guidelines for the treatment of malaria , 2010 .

[2]  R. Price,et al.  Antimalarial therapies in children from Papua New Guinea. , 2009, The New England journal of medicine.

[3]  P. Siba,et al.  A trial of combination antimalarial therapies in children from Papua New Guinea. , 2008, The New England journal of medicine.

[4]  T. Travers,et al.  Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. , 2008, The American journal of tropical medicine and hygiene.

[5]  David L. Smith,et al.  Benefits of using multiple first-line therapies against malaria , 2008, Proceedings of the National Academy of Sciences.

[6]  M. Ashton,et al.  The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. , 2008, Acta tropica.

[7]  P. Rosenthal,et al.  Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treating Uncomplicated Malaria: A Randomized Trial to Guide Policy in Uganda , 2008, PloS one.

[8]  N. White.  How antimalarial drug resistance affects post-treatment prophylaxis , 2008, Malaria Journal.

[9]  P. Rosenthal,et al.  Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  F. Nosten,et al.  Artemisinin-based combination treatment of falciparum malaria. , 2007, The American journal of tropical medicine and hygiene.

[11]  U. d’Alessandro,et al.  A Randomised Controlled Trial to Assess the Efficacy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Peru , 2007, PloS one.

[12]  R. Price,et al.  Clinical and Pharmacological Determinants of the Therapeutic Response to Dihydroartemisinin-Piperaquine for Drug-Resistant Malaria , 2007, Antimicrobial Agents and Chemotherapy.

[13]  H. Myint,et al.  Efficacy and safety of dihydroartemisinin-piperaquine. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[14]  P. Rosenthal,et al.  Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial , 2007, PLoS clinical trials.

[15]  R. Price,et al.  Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Price,et al.  Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison , 2007, The Lancet.

[17]  C. Karema,et al.  Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[18]  K. Stepniewska,et al.  Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison , 2006, The Lancet.

[19]  U. d’Alessandro,et al.  Pharmacovigilance of antimalarial treatment in Africa: is it possible? , 2006, Malaria Journal.

[20]  Douglas G Altman,et al.  Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. , 2006, JAMA.

[21]  T. Davis,et al.  Effects of a High-Fat Meal on the Relative Oral Bioavailability of Piperaquine , 2005, Antimicrobial Agents and Chemotherapy.

[22]  R. Hallett,et al.  Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial , 2005, The Lancet.

[23]  Inacio Mandomando,et al.  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.

[24]  Nicholas J White,et al.  Antimalarial drug resistance. , 2004, The Journal of clinical investigation.

[25]  P. Alonso,et al.  Efficacy of chloroquine, amodiaquine, sulphadoxine–pyrimethamine and combination therapy with artesunate in Mozambican children with non‐complicated malaria , 2004, Tropical medicine & international health : TM & IH.

[26]  S. Satpathy,et al.  Severe falciparum malaria , 2004, Indian journal of pediatrics.

[27]  U. d’Alessandro,et al.  History, Dynamics, and Public Health Importance of Malaria Parasite Resistance , 2004, Clinical Microbiology Reviews.

[28]  R. Snow,et al.  Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria , 2003 .

[29]  A. Talisuna,et al.  Clinical efficacy of chloroquine or sulfadoxine-pyrimethamine in children under five from south-western Uganda with uncomplicated falciparum malaria. , 2002, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[30]  N. White,et al.  Pharmacokinetics and Pharmacodynamics of Lumefantrine (Benflumetol) in Acute Falciparum Malaria , 2000, Antimicrobial Agents and Chemotherapy.

[31]  K. Raynes.  Bisquinoline antimalarials: their role in malaria chemotherapy. , 1999, International journal for parasitology.

[32]  R. Paru,et al.  Mating patterns in malaria parasite populations of Papua New Guinea. , 1995, Science.

[33]  P Roebruck,et al.  Comparison of tests and sample size formulae for proving therapeutic equivalence based on the difference of binomial probabilities. , 1995, Statistics in medicine.

[34]  O. Doumbo,et al.  Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. , 1995, The American journal of tropical medicine and hygiene.

[35]  R. Carter,et al.  Frequency of cross-fertilization in the human malaria parasite Plasmodium falciparum , 1993, Parasitology.

[36]  J. Philpott,et al.  Severe falciparum malaria. , 1987, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.